|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The first part of this review article focuses on the role of pancreatic-derived PLA2G1B in mediating lipid absorption and discusses how the PLA2G1B-derived metabolic product contributes to cardiometabolic diseases, including obesity, hyperinsulinemia, hyperlipidemia, and atherosclerosis.
|
30003964 |
2019 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Low-density lipoprotein modified either by oxidation (oxLDL) or by human group X-secreted phospholipase A2 (LDLx) and heat shock proteins (HSP), especially HSP60 and 90, have been implicated in atherosclerosis.
|
25395618 |
2015 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our study identifies a previously unknown proteolytic activity of PLA2 that is specific to apoA-I and may contribute to the enhanced catabolism of apoA-I in inflammation and atherosclerosis.
|
24523407 |
2014 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Group X secreted phospholipase A2 limits the development of atherosclerosis in LDL receptor-null mice.
|
23349189 |
2013 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Surprisingly, however, administration of varespladib acid to TTT had no impact on atherosclerosis, which could be attributed to a proatherogenic plasma lipoprotein profile that appears in response to sPLA2-IIA inhibition because of increased plasma CETP activity.
|
24115030 |
2013 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently completed experimental animal studies, human biomarker data, vascular imaging studies, and genome-wide atherosclerosis studies provide the rationale for proceeding with clinical outcome trials directed at inhibition of secretory phospholipase A(2) and lipoprotein-associated phospholipase A(2).
|
22802388 |
2012 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We aimed to explore the effect of PlA2 polymorphism on outcome in patients with atherosclerosis.
|
20846430 |
2010 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Secreted phospholipase A2 type IIA as a mediator connecting innate and adaptive immunity: new role in atherosclerosis.
|
18755682 |
2009 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The coexistence of both 807 T and PlA2 alleles increased the arterial thrombosis risk in patients with APS and preclinical arteriosclerosis in patients with SLE.
|
17728329 |
2008 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The findings of this study suggest that Pl(A1/A1) homozygotes may be prone to early atherosclerosis and more rapid progression of stable CAD whereas carriers of the PlA2 allele are more prone to thrombotic complications.
|
11257275 |
2001 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consequently, our results indicate a potential role for both cytosolic and secretory PLA(2) enzymes in inflammation and in macrophage functions related to atherosclerosis, with a specific role for group IIa snpPLA2 in LDL scavenging.
|
10807743 |
2000 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids.
|
10323782 |
1999 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2.
|
10323781 |
1999 |